Open AccessA new delivery device for benralizumab (autoinjector, pen-injector device) in the clinical practice of treating severe eosinophilic asthma: Conclusion of the Expert Council
Author(s) -
S. N. Avdeev,
A. V. Еmelyanov,
О М Курбачева,
И. М. Марусенко,
Pavel Novikov,
Olga A. Rizakhanova,
Л. В. Шульженко
Publication year - 2021
Publication title -
pulʹmonologiâ
Language(s) - English
Resource type - Journals
eISSN - 2541-9617
pISSN - 0869-0189
DOI - 10.18093/0869-0189-2021-31-6-776-781
Subject(s) - medicine , benralizumab , intensive care medicine , eosinophilic , asthma , pathology , mepolizumab , eosinophil
The emergence of new means of administering genetically-engineered biological drugs, such as an autoinjector (pen injector device), can positively affect the organizational aspects of treating patients with severe eosinophilic asthma (SA) who need biological therapy. The aim . To determine the place of a new delivery device for benralizumab (autoinjector, pen injector device) in the clinical practice of treating eosinophilic SA. Results. The expert council considered the results of the latest clinical studies and real practice data on the use of genetically-engineered biological drugs in the form of an autoinjector. The experts discussed the safety and efficacy of this delivery device and recommended considering the possibility of switching eosinophilic SA patients to self-administration of genetically-engineered biological drugs (autoinjector form) at home. This treatment tactic is especially relevant in the current epidemiological situation since it will reduce the risks of infection compared to planned medical care in inpatient or outpatient treatment settings and reduce the burden for healthcare workers. Conclusion. The practice of switching eosinophilic SA patients to self-administration of biologics in the form of an autoinjector (pen injector device) can improve the adherence to biological therapy and quality of life of this group of patients.